IV ketamine for Boynton Beach — psychiatry-supervised, integrated with therapy.

Boynton Beach residents live seven miles — twelve minutes — from RECO Health's Delray Beach location. The ketamine program is psychiatry-supervised throughout: 0.5 mg/kg IV over 40 minutes, continuous vital-sign and CADSS monitoring, six infusions across two to three weeks, and matched next-day integration sessions with a therapist trained in the modality. Spravato is offered alongside IV ketamine, so the decision is not forced by what a given clinic happens to stock. The full psychiatric continuum — medication management, TMS, and therapy — is in the same building, which matters when ketamine is one component of a larger treatment plan.

Boynton Beach sits seven miles north of Delray Beach along Federal Highway. For residents in Renaissance Commons, Ocean Ridge, or Quantum Park, the twelve-minute drive south to RECO Health is often shorter than the trip to a Boynton supermarket — short enough that a two-hour ketamine infusion followed by a next-day integration session fits inside an existing daily life without uprooting work or family routines. What follows describes how RECO Health delivers IV ketamine therapy for treatment-resistant depression, acute suicidality, and refractory PTSD, and how the protocol integrates with the rest of a psychiatric treatment plan.

Ketamine’s mechanism and why it works fast

Ketamine is a non-competitive NMDA receptor antagonist. Its antidepressant effect is not primarily attributable to that receptor blockade in isolation; the clinically meaningful downstream signal involves increased AMPA receptor throughput, a rapid rise in brain-derived neurotrophic factor (BDNF), and measurable synaptogenesis in the medial prefrontal cortex within hours of infusion. That mechanism is categorically different from SSRIs like sertraline or escitalopram, which act on presynaptic serotonin reuptake and require four to six weeks before symptom change is visible on a PHQ-9.

The speed matters. In treatment-resistant depression — inadequate response to two or more adequate antidepressant trials — waiting six weeks for the next SSRI to fail is often not a neutral option. In patients presenting with active suicidal ideation on the C-SSRS, the timeline is more compressed still. Ketamine’s antidepressant and anti-suicidal effect emerges within hours to days in the published literature, which is why it occupies a specific role in the TRD algorithm and the acute crisis pathway — not as a first-line agent, but as the pharmacologic tool that closes the gap when time-to-response is the clinical constraint.

That framing determines candidacy. Ketamine is not an alternative to a first SSRI trial in new-onset moderate depression. It is what we reach for when the PHQ-9 has not moved after adequate trials, when augmentation with aripiprazole or lithium has been tried or ruled out, or when suicidality is driving the clinical picture.

The 40-minute infusion, monitored recovery, and the six-session induction

Each session runs roughly two hours end-to-end. Intake includes vital signs, a brief mood and suicidality reassessment, and confirmation of transportation home. The infusion itself is 0.5 mg/kg of ketamine delivered intravenously over 40 minutes, weight-adjusted, with occasional titration up or down based on prior session response. Blood pressure, heart rate, and oxygen saturation are monitored continuously; dissociative symptoms are assessed with the Clinician-Administered Dissociative States Scale (CADSS) so response profiles are documented consistently across the induction.

After the infusion, clients spend 30 to 60 minutes in monitored recovery until vitals return to baseline and dissociation has fully resolved. Driving is not permitted the day of infusion — residual dissociative and hemodynamic effects can persist below subjective awareness for several hours. Every client leaves with a family member or an arranged rideshare.

The induction series is six infusions across two to three weeks. That interval is where sustained response either consolidates or does not. Response is tracked with PHQ-9, GAD-7, and PCL-5 where PTSD is a primary target. Clients who respond during induction transition to a maintenance schedule — single-infusion boosters at intervals from every two weeks to every six weeks, set by observed response duration.

Integration with psychotherapy makes response durable

Ketamine opens a window; therapy determines whether the client walks through it. The infusion produces a period of enhanced neuroplasticity and, in many clients, a temporary relaxation of the depressive or trauma-driven cognitive frames that structure symptom persistence. That period is where change becomes possible — but change does not consolidate on its own. Ketamine without integration produces shorter response duration and higher relapse rates in the published literature, which is why RECO’s protocol pairs every infusion with a next-day integration session.

The therapeutic modality is matched to the presenting problem: CBT and behavioral activation for depressive cognition and withdrawal; ACT for values clarification and defusion from rumination; EMDR for trauma material that surfaces during infusion; MI where ambivalence about behavior change is a barrier to response. For clients whose depression is entangled with substance use, integration also addresses cravings and relapse triggers directly, with DBT distress tolerance skills where affective dysregulation is prominent.

Ketamine vs Spravato and how we decide

IV ketamine is off-label — the FDA-approved indications for ketamine are anesthetic — which means it is almost always cash-pay. Spravato (esketamine) is FDA-approved for treatment-resistant depression and for major depressive disorder with acute suicidal ideation, and it is covered by most commercial insurance plans under a REMS protocol requiring in-office administration and post-dose observation.

The practical differences: Spravato is intranasal, twice-weekly for the first four weeks, then tapering to weekly and every-other-week during maintenance. IV ketamine offers dose flexibility, a compressed induction schedule of six sessions in two to three weeks, and a somewhat different subjective and response profile in the clinical experience of many prescribers. When insurance coverage is the deciding factor and the longer Spravato induction is workable, Spravato is typically the right choice; when dose flexibility or a compressed schedule matters more, IV ketamine is preferred. RECO offers both, and the decision is made with the client during the psychiatry consult, informed by insurance verification, the clinical picture, and travel constraints from Boynton Beach.

What to expect on your first visit

The first visit is a psychiatry consult, not an infusion. The psychiatrist reviews prior treatment history, current medications, and any medical comorbidities — uncontrolled hypertension, unstable cardiac disease, or active substance use can shift protocol or defer treatment. Standardized assessments (PHQ-9, GAD-7, C-SSRS, and PCL-5 where relevant) establish a symptom baseline that subsequent sessions are measured against.

Consent is reviewed in detail, including the dissociative experience, the driving restriction, and realistic response and non-response rates for the presenting diagnosis. If IV ketamine is the agreed course, the six-session induction and matched integration sessions are scheduled across the following two to three weeks. If Spravato fits better, insurance verification and REMS enrollment begin the same day. Clients from Boynton Beach traveling seven miles south for the consult typically leave with a scheduled first infusion within the same week.

Insurance and admissions from Boynton Beach

Spravato is covered under most commercial plans — Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS — subject to prior authorization and documented TRD criteria. IV ketamine is typically cash-pay; single-infusion and induction-package pricing is quoted during the intake call. The route from Boynton Beach is a straight run south on Federal Highway or I-95 — twelve minutes door-to-door from Renaissance Commons, and comparable from Ocean Ridge, Quantum Park, Hunters Run, and Briny Breezes.

Serving residents of: Renaissance Commons, Ocean Ridge, Quantum Park, Hunters Run, Briny Breezes.